title: Novel target in the treatment of RPGN: the activated parietal cell.
abstract: Iyoda et al. have provided strong experimental evidence for beneficial effects of PDGF signalling inhibition in two seemingly unrelated glomerular diseases: rapidly progressive glomerulonephritis (RPGN) in the present study and focal and segmental glomerulosclerosis (FSGS) in a previous study. Novel insights into the pathogenesis of these two diseases have unravelled a common cellular mechanism: activation of parietal epithelial cells (PECs). In addition, recent studies have shown that PDGF signalling is sufficient to mediate the PEC activation and formation of cellular crescents, the hallmark of RPGN. In this comment, we make an attempt to assemble the pieces of the puzzle arguing that the activated PECs might play a significant role and could represent a target for novel treatment strategies for RPGN and FSGS.
authors.affiliation: University Hospital of the Aachen University of Technology, Aachen, Germany. mmoeller@ukaachen.de
authors.forename: Marcus J
authors.initials: MJ
authors.lastname: Moeller
authors.forename: Bart
authors.initials: B
authors.lastname: Smeets
mesh_terms: D000818:Animals; D019867:Anti-Glomerular Basement Membrane Disease / Q000150:complications*; D001549:Benzamides / Q000627:therapeutic use*; D005260:Female; D000068877:Imatinib Mesylate; D010879:Piperazines / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D051436:Renal Insufficiency, Chronic / Q000517:prevention & control*
chemical_list: D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate